Compare ACRS & MTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | MTRX |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 342.7M |
| IPO Year | 2015 | 1995 |
| Metric | ACRS | MTRX |
|---|---|---|
| Price | $4.98 | $12.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.20 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.3M | 221.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $769,286,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $4.24 | $7.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.64 |
| 52 Week Low | $1.22 | $9.88 |
| 52 Week High | $5.12 | $16.11 |
| Indicator | ACRS | MTRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.69 | 48.40 |
| Support Level | $2.67 | $12.09 |
| Resistance Level | N/A | $13.17 |
| Average True Range (ATR) | 0.27 | 0.59 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 86.45 | 29.20 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.